Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic
Cancer

J 2015

Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer

BOJKOVÁ, Martina, Petr DÍTĚ, Jana DVOŘÁČKOVÁ, Ivo NOVOTNÝ, Katarína FLOREÁNOVÁ et. al.

Základní údaje

Originální název

Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer

Autoři

BOJKOVÁ, Martina (203 Česká republika), Petr DÍTĚ (203 Česká republika), Jana DVOŘÁČKOVÁ (203 Česká republika), Ivo NOVOTNÝ (203 Česká republika), Katarína FLOREÁNOVÁ (203 Česká republika, domácí), Bohuslav KIANIČKA (203 Česká republika, garant, domácí), Magdalena UVÍROVÁ (203 Česká republika) a Arnošt MARTÍNEK (203 Česká republika)

Vydání

Digestive Diseases, Basel, Karger, 2015, 0257-2753

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.777

Kód RIV

RIV/00216224:14110/15:00082328

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1159/000368337

UT WoS

000346891600011

Klíčová slova anglicky

Immunoglobulin G4; Autoimmune pancreatitis; Pancreatic cancer

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 7. 2015 13:52, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: Immunoglobulin G4 (IgG4)-related diseases are a group of diseases characterized by enlargement of the affected organs, elevation of serum IgG4, massive infiltration of affected organs with lymphocytes and plasma cells with IgG4 positivity and tissue fibrosis. Type I autoinnmune pancreatitis is one form of IgG4-related disease. For IgG4-related diseases, various localizations are described for up to 10% of malignancies. The aim of our study was to examine IgG4 serum levels and pancreatic tissue with respect to the simultaneous presence of autoimmune pancreatitis in patients with pancreatic cancer. Methods: IgG4 serum levels were examined In 106 patients with histologically confirmed pancreatic cancer. The level of 135 mg/dl was considered as the normal value. Pancreatic tissue was histologically examined with respect to the presence of markers of autoimmune pancreatitis. Results: A higher IgG4 level than the cut-off value of 135 mg/dl was proven in 11 patients with pancreatic cancer. Of these 11 patients, 7 had levels twice the normal limit (65.6%). Autoimmune pancreatitis was diagnosed in these individuals. In the case of 1 patient, it was basically an unexpected finding; another patient was initially diagnosed with autoimmune pancreatitis. Repeated biopsy of the pancreas at the time of diagnosis did not confirm the presence of tumour structures, therefore steroid therapy was started. At a check-up 6 months after starting steroid therapy, the condition of the patient improved subjectively and IgG4 levels decreased. However, endosonographically, malignancy was suspected, which was subsequently confirmed histologically. This patient also demonstrated an IgG4 level twice the normal limit. Conclusion: IgG4-related diseases can be accompanied by the simultaneous occurrence of malignancies, which also applies to autoimmune pancreatitis. Chronic pancreatitis is considered a risk factor for pancreatic cancer. It cannot be reliably confirmed whether this also applies to autoimmune pancreatitis. In accordance with other works, however, it is evident that, despite the described high sensitivity and specificity for IgG4 elevation in the case of autoimmune pancreatitis, even levels twice the normal limit are demonstrable in some individuals with pancreatic cancer, without the presence of autoimmune pancreatitis. We believe that patients with IgG4-related disease, including autoimmune pancreatitis, must be systematically monitored with respect to the potential presence of malignancy. (C) 2014 S. Karger AG, Basel

Citovat

BOJKOVÁ, Martina, Petr DÍTĚ, Jana DVOŘÁČKOVÁ, Ivo NOVOTNÝ, Katarína FLOREÁNOVÁ, Bohuslav KIANIČKA, Magdalena UVÍROVÁ a Arnošt MARTÍNEK. Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer. Digestive Diseases. Basel: Karger, 2015, roč. 33, č. 1, s. 86-90. ISSN 0257-2753. Dostupné z: https://dx.doi.org/10.1159/000368337.

@article{1219945,
   author = {Bojková, Martina and Dítě, Petr and Dvořáčková, Jana and Novotný, Ivo and Floreánová, Katarína and Kianička, Bohuslav and Uvírová, Magdalena and Martínek, Arnošt},
   article_location = {Basel},
   article_number = {1},
   doi = {http://dx.doi.org/10.1159/000368337},
   keywords = {Immunoglobulin G4; Autoimmune pancreatitis; Pancreatic cancer},
   language = {eng},
   issn = {0257-2753},
   journal = {Digestive Diseases},
   title = {Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer},
   volume = {33},
   year = {2015}
}

TY  - JOUR
ID  - 1219945
AU  - Bojková, Martina - Dítě, Petr - Dvořáčková, Jana - Novotný, Ivo - Floreánová, Katarína - Kianička, Bohuslav - Uvírová, Magdalena - Martínek, Arnošt
PY  - 2015
TI  - Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer
JF  - Digestive Diseases
VL  - 33
IS  - 1
SP  - 86-90
EP  - 86-90
PB  - Karger
SN  - 02572753
KW  - Immunoglobulin G4
KW  - Autoimmune pancreatitis
KW  - Pancreatic cancer
N2  - Background: Immunoglobulin G4 (IgG4)-related diseases are a group of diseases characterized by enlargement of the affected organs, elevation of serum IgG4, massive infiltration of affected organs with lymphocytes and plasma cells with IgG4 positivity and tissue fibrosis. Type I autoinnmune pancreatitis is one form of IgG4-related disease. For IgG4-related diseases, various localizations are described for up to 10% of malignancies. The aim of our study was to examine IgG4 serum levels and pancreatic tissue with respect to the simultaneous presence of autoimmune pancreatitis in patients with pancreatic cancer. Methods: IgG4 serum levels were examined In 106 patients with histologically confirmed pancreatic cancer. The level of 135 mg/dl was considered as the normal value. Pancreatic tissue was histologically examined with respect to the presence of markers of autoimmune pancreatitis. Results: A higher IgG4 level than the cut-off value of 135 mg/dl was proven in 11 patients with pancreatic cancer. Of these 11 patients, 7 had levels twice the normal limit (65.6%). Autoimmune pancreatitis was diagnosed in these individuals. In the case of 1 patient, it was basically an unexpected finding; another patient was initially diagnosed with autoimmune pancreatitis. Repeated biopsy of the pancreas at the time of diagnosis did not confirm the presence of tumour structures, therefore steroid therapy was started. At a check-up 6 months after starting steroid therapy, the condition of the patient improved subjectively and IgG4 levels decreased. However, endosonographically, malignancy was suspected, which was subsequently confirmed histologically. This patient also demonstrated an IgG4 level twice the normal limit. Conclusion: IgG4-related diseases can be accompanied by the simultaneous occurrence of malignancies, which also applies to autoimmune pancreatitis. Chronic pancreatitis is considered a risk factor for pancreatic cancer. It cannot be reliably confirmed whether this also applies to autoimmune pancreatitis. In accordance with other works, however, it is evident that, despite the described high sensitivity and specificity for IgG4 elevation in the case of autoimmune pancreatitis, even levels twice the normal limit are demonstrable in some individuals with pancreatic cancer, without the presence of autoimmune pancreatitis. We believe that patients with IgG4-related disease, including autoimmune pancreatitis, must be systematically monitored with respect to the potential presence of malignancy. (C) 2014 S. Karger AG, Basel
ER  -

BOJKOVÁ, Martina, Petr DÍTĚ, Jana DVOŘÁČKOVÁ, Ivo NOVOTNÝ, Katarína FLOREÁNOVÁ, Bohuslav KIANIČKA, Magdalena UVÍROVÁ a Arnošt MARTÍNEK. Immunoglobulin G4, Autoimmune Pancreatitis and Pancreatic Cancer. \textit{Digestive Diseases}. Basel: Karger, 2015, roč.~33, č.~1, s.~86-90. ISSN~0257-2753. Dostupné z: https://dx.doi.org/10.1159/000368337.

Podrobný výpis o publikaci